Literature DB >> 21453879

Prevalence and risk factors of hyperhomocysteinemia in Tunisian patients with Crohn's disease.

Lamia Kallel1, Moncef Feki, Wirak Sekri, Lamia Segheir, Monia Fekih, Jalel Boubaker, Naziha Kaabachi, Azza Filali.   

Abstract

BACKGROUND AND AIMS: The role of hyperhomocysteinemia (HHC) and its determinants in Crohn's disease (CD) remain uncertain. This study was aimed to determine the prevalence of HHC and its main risk factors in Tunisian patients with CD.
METHODS: This study included 89 patients with CD and 103 age- and sex-matched healthy subjects. Fasting venous blood was collected in all subjects allowing the assessment of homocysteine, folate, vitamin B(12), C-reactive protein and creatinine levels. Logistic regression models were applied to identify factors associated with HHC in CD patients.
RESULTS: Plasma homocysteine was higher (13.69 ± 4.84μmol/l vs. 10.77 ± 2.80μmol/l; p<0.01) and HHC was more frequent (31.5% vs. 7.8%; p<0.001) in patients compared with controls. The association between HHC and CD persisted after adjustment for smoking, body mass index and serum folate, vitamin B(12), creatinine and C-reactive protein. In patients with CD, multivariate analysis showed that HHC was positively associated with age [multi-adjusted odds-ratio (95% confidence interval): 1.14 (1.06-1.24); p<0.001], active disease [7.54 (1.15-49.3); p=0.03], disease duration >2 years [8.69 (1.53-49.3); p=0.02] and inversely related to plasma folate [0.64 (0.48-0.84); p=0.002] and vitamin B(12) (0.993 (0.987-0.999); p=0.02].
CONCLUSION: HHC is common in Tunisian patients with CD and is related to B vitamins deficit, as well as disease activity and duration. Further studies should test the effect of correction of HHC by vitamin B supplementation on progression and complications of CD.
Copyright © 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21453879     DOI: 10.1016/j.crohns.2010.10.010

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  8 in total

Review 1.  Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review.

Authors:  Ammar Hassanzadeh Keshteli; Vickie E Baracos; Karen L Madsen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  Association of ulcerative colitis with transcobalamin II gene polymorphisms and serum homocysteine, vitamin B12, and folate levels in Chinese patients.

Authors:  Shuzi Zheng; Wei Yang; Chaoqun Wu; Liang Sun; Daopo Lin; Xiuqing Lin; Lijia Jiang; Ran Ding; Yi Jiang
Journal:  Immunogenetics       Date:  2017-05-19       Impact factor: 2.846

3.  Homocysteine promotes intestinal fibrosis in rats with trinitrobenzene sulfonic acid-induced colitis.

Authors:  Hao Ding; Hui-Zhong Gan; Wen-Jie Fan; Li-Yu Cao; Jian-Ming Xu; Qiao Mei
Journal:  Dig Dis Sci       Date:  2014-10-08       Impact factor: 3.199

4.  Effect of Homocysteine on the Differentiation of CD4+ T Cells into Th17 Cells.

Authors:  Xin Gao; Jin Li; Min Chen
Journal:  Dig Dis Sci       Date:  2018-07-04       Impact factor: 3.199

5.  Hyperhomocysteinemia in patients with Crohn's disease.

Authors:  G Casella; E Antonelli; C Di Bella; E Di Marco; M Piatti; V Villanacci; S Bologna; V Baldini; G Bassotti
Journal:  Tech Coloproctol       Date:  2013-03-08       Impact factor: 3.781

Review 6.  Associations between Folate and Vitamin B12 Levels and Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Yun Pan; Ya Liu; Haizhuo Guo; Majid Sakhi Jabir; Xuanchen Liu; Weiwei Cui; Dong Li
Journal:  Nutrients       Date:  2017-04-13       Impact factor: 5.717

7.  Status of serum vitamin B12 and folate in patients with inflammatory bowel disease in China.

Authors:  Shaozhong Huang; Jiayi Ma; Mingming Zhu; Zhihua Ran
Journal:  Intest Res       Date:  2017-01-31

Review 8.  Inflammatory bowel disease: an expanding global health problem.

Authors:  Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2013-08-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.